US00847G7051 - Common Stock - After market: 2.67 +0.06 (+2.3%)
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting...
Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated patients; data suggest superior...
LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics...
With major macroeconomic headwinds appearing on the horizon, it’s time for investors to consider the hot stocks to book profits in.
Agenus presented data this week on a combination therapy.
Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of...
LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and...
Immuno-oncology company Agenus Inc. (AGEN) added ~11% on Monday after announcing data from a Phase 1 study for cancer candidates botensilimab and balstilimab in patients with...
Overall response rates ranged from 22% in microsatellite stable colorectal cancer (MSS-CRC) to 60% in PD-(L)1 refractory non-small cell lung cancer...
AGEN earnings call for the period ending September 30, 2022.
Company to present expanded data from Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) at plenary session of the Society for Immunotherapy of Cancer...
Conference Call on Tuesday, November 8, 2022, at 8:30 a.m. ETCompany to host “The Road Taken” R&D Event in Boston on November 12 from 2p.m. – 5p.m. ET...
Data show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with consistent high...